Premium
Resveratrol in the treatment of pancreatic cancer
Author(s) -
Xu Qinhong,
Zong Liang,
Chen Xin,
Jiang Zhengdong,
Nan Ligang,
Li Jiahui,
Duan Wanxing,
Lei Jianjun,
Zhang Lun,
Ma Jiguang,
Li Xuqi,
Wang Zheng,
Wu Zheng,
Ma Qingyong,
Ma Zhenhua
Publication year - 2015
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12837
Subject(s) - resveratrol , pancreatic cancer , medicine , apoptosis , cancer , cancer research , metastasis , cancer cell , viability assay , cell cycle , oncology , lymph node , pharmacology , biology , biochemistry
Pancreatic cancer (PCa), which is now the fourth most frequent cause of cancer‐related death, has a median survival of less than 6 months and a 5‐year survival rate of <6%. The hallmarks of this cancer include poor outcome, short survival duration, and resistance to therapy. The poor prognosis of PCa is related to its local recurrence, lymph node and liver metastases, and peritoneal dissemination. Recent studies have indicated that resveratrol has cancer‐chemopreventive and anticancer activities. In this short review we summarize the chemopreventive and treatment effects of resveratrol in PCa, as follows: resveratrol inhibits the proliferation of pancreatic cancer cells; induces apoptosis and cell cycle arrest; inhibits metastasis and invasion of PCa cells; inhibits the proliferation and viability of PCa stem cells; enhances the chemoradiosensitization of PCa cells; and can affect diabetes mellitus in addition to PCa. On the basis of these data, resveratrol may be considered a potential anticancer agent for the treatment of PCa.